<DOC>
	<DOC>NCT00784693</DOC>
	<brief_summary>The purpose of this study is to determine whether tanezumab is effective and safe in the treatment of pain associated with endometriosis.</brief_summary>
	<brief_title>A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Premenstrual women with moderate to severe endometriosis. The diagnosis of endometriosis must have been confirmed surgically within the last 8 years. Subjects should have regular menstrual cycle (21 35 days) and must be willing to use adequate contraception (2 forms of birth control, one of which must be a barrier method). Contraception is required throughout the study (screening to 16 weeks post treatment), even if subjects discontinue prematurely. Previous hysterectomy Surgical treatment for endometriosis within last 6 months. Medical treatment for endometriosis other than combined oral contraceptive pill within the last 3 months Current use of the coil or progesterone only contraceptive (the combined oral contraceptive pill is allowed). Any history of malignant disease (cancer)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>pain</keyword>
	<keyword>tanezumab</keyword>
	<keyword>nerve growth factor</keyword>
	<keyword>questionnaires</keyword>
</DOC>